Fabrication and efficacy assessment of combination of brimonidine and ivermectin for treatment of papulopustular rosacea
Open Access
- 3 June 2024
- journal article
- research article
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 23 (9) , 2973-2981
Abstract
Background & Aim: Rosacea is a chronic inflammatory, multifactorial disease for which combination therapy could be an effective treatment. In this study, we evaluate the effect of the combination therapy of brimonidine 0.33% and ivermectin 1% as a single cream for the treatment of papulopustular rosacea. Method: A stable and appropriate formulation was prepared by adding the aqueous phase to the lipid phase while being stirred. The stability and physicochemical properties of the formulation were evaluated under accelerated conditions. Twelve patients (36–60 years) with mild to moderate papulopustular rosacea and a Demodex count of five or more were treated with the combination of brimonidine 0.33% and ivermectin 1% cream. Clinician's Erythema Assessment (CEA), Patients Self‐Assessment (PSA), skin erythema (ΔE) and lightness (ΔL), and skin biophysical parameters including transepidermal water loss (TEWL), skin hydration, pH, and sebum content, as well as erythema and melanin index and ultrasound parameters, were measured before treatment and 4 and 8 weeks after. Adverse drug reactions were also recorded. Results: CEA and PSA decreased significantly from 3 to 2 after 8 weeks, respectively ( p ‐value = 0.014 for CEA and 0.010 for PSA). ΔE and ΔL, as well as skin erythema index and TEWL improved after 8 weeks of treatment ( p < 0.05). Two patients withdrew from the study in the first week because of local adverse effects; one developed flushing following treatment and left the investigation after 4 weeks and another patient withdrew from the study after 4 weeks due to deciding to become pregnant. Conclusion: Eight‐week treatment with the combination of brimonidine 0.33% and ivermectin 1% was shown to be effective for improvement of erythema and inflammatory lesions in mild to moderate papulopustular rosacea.Keywords
Funding Information
- National Institute for Medical Research Development (988037)
This publication has 15 references indexed in Scilit:
- Rosacea: New Concepts in Classification and TreatmentAmerican Journal of Clinical Dermatology, 2021
- Topical Ivermectin in the Treatment of Papulopustular Rosacea: A Systematic Review of Evidence and Clinical Guideline RecommendationsDermatology and Therapy, 2018
- Rosacea treatment update: recommendations from the global ROS acea CO nsensus ( ROSCO ) panelBritish Journal of Dermatology, 2016
- Brimonidine gel 0.33% rapidly improves patient‐reported outcomes by controlling facial erythema of rosacea: a randomized, double‐blind, vehicle‐controlled studyJournal of the European Academy of Dermatology and Venereology, 2015
- The psychological impact of rosacea and the influence of current management optionsJournal of the American Academy of Dermatology, 2014
- Brimonidine effective but may lead to significant rebound erythemaJournal of the American Academy of Dermatology, 2014
- New insights into rosacea pathophysiology: A review of recent findingsJournal of the American Academy of Dermatology, 2013
- Potential role of Demodex mites and bacteria in the induction of rosaceaJournal of Medical Microbiology, 2012
- Bacillus oleronius and Demodex mite infestation in patients with chronic blepharitisClinical Microbiology and Infection, 2012
- The significance ofDemodex folliculorumdensity in rosaceaInternational Journal of Dermatology, 1998